The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Ironwood Pharmaceuticals Inc’s stock clocked out at $1.43, down -7.74% from its previous closing price of $1.55. In other words, the price has decreased by -$7.74 from its previous closing price. On the day, 1.05 million shares were traded. IRWD stock price reached its highest trading level at $1.5651 during the session, while it also had its lowest trading level at $1.43.
Ratios:
To gain a deeper understanding of IRWD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.76. For the most recent quarter (mrq), Quick Ratio is recorded 0.82 and its Current Ratio is at 0.82.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 11 ’25 when Gaskins Tammi L sold 1,316 shares for $0.84 per share. The transaction valued at 1,105 led to the insider holds 241,280 shares of the business.
John Minardo sold 7,754 shares of IRWD for $6,513 on Aug 11 ’25. The Chief Legal Officer now owns 400,378 shares after completing the transaction at $0.84 per share. On Aug 11 ’25, another insider, Martini Gregory S., who serves as the Chief Financial Officer of the company, sold 1,265 shares for $0.84 each. As a result, the insider received 1,063 and left with 182,545 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 232280800 and an Enterprise Value of 738097792. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.75. Its current Enterprise Value per Revenue stands at 2.392 whereas that against EBITDA is 7.879.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.30, which has changed by -0.6587112 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $5.13, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 9.55%, while the 200-Day Moving Average is calculated to be 1.30%.
Shares Statistics:
It appears that IRWD traded 1.36M shares on average per day over the past three months and 1174630 shares per day over the past ten days. A total of 162.43M shares are outstanding, with a floating share count of 156.35M. Insiders hold about 3.74% of the company’s shares, while institutions hold 90.00% stake in the company. Shares short for IRWD as of 1759190400 were 5166794 with a Short Ratio of 3.79, compared to 1756425600 on 6063890. Therefore, it implies a Short% of Shares Outstanding of 5166794 and a Short% of Float of 4.82.
Earnings Estimates
As of right now, 1.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.11, with high estimates of $0.11 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.21 and $0.21 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.21, with 3.0 analysts recommending between $0.41 and $0.0.
Revenue Estimates
In. The current quarter, 4 analysts expect revenue to total $75.53M. It ranges from a high estimate of $83.4M to a low estimate of $68.4M. As of. The current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $91.59MFor the next quarter, 4 analysts are estimating revenue of $77.5M. There is a high estimate of $84M for the next quarter, whereas the lowest estimate is $70M.
A total of 4 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $275.2M, while the lowest revenue estimate was $273.8M, resulting in an average revenue estimate of $274.38M. In the same quarter a year ago, actual revenue was $351.41MBased on 4 analysts’ estimates, the company’s revenue will be $257.55M in the next fiscal year. The high estimate is $285M and the low estimate is $225.8M.
